Reversibility of 'secondary hypercalcitoninemia' after kidney transplantation

被引:19
作者
Borchhardt, KA [1 ]
Hörl, WH [1 ]
Sunder-Plassmann, G [1 ]
机构
[1] Med Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Vienna, Austria
关键词
calcitonin; C-cell hyperplasia; chronic kidney disease; kidney transplantation; pentagastrin; thyroid gland;
D O I
10.1111/j.1600-6143.2005.00908.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Whether the increase of calcitonin (CT) concentration in patients with chronic kidney disease (CKD) is reversible or not after kidney transplantation is not known. We examined the effect of kidney transplantation on basal and pentagastrin-stimulated CT in CKD patients with elevated screening CT levels. Before transplantation, the median basal CT concentration of 17 patients was 31 pg/mL (13-76), and decreased to 8 pg/mL (4-28) at 23 months (2-34) after kidney transplantation (p < 0.00005). The maximum concentration of pentagastrin-stimulated CT was 63 pg/mL (25-110) before transplantation and decreased to 20 pg/mL (8-91) (p < 0.00005) thereafter. There was a linear association between CT and calcium as well as between phosphorus and parathyroid hormone at the time of screening. After transplantation, CT correlated with serum creatinine. Therefore, the increase of CT concentration in patients with impaired kidney function presumably reflects 'secondary hypercalcitoninemia' due to C-cell hyperactivity.
引用
收藏
页码:1757 / 1763
页数:7
相关论文
共 28 条
[1]  
Azzadin A, 2001, FOLIA HISTOCHEM CYTO, V39, P203
[2]   PENTAGASTRIN STIMULATION TEST AND EARLY DIAGNOSIS OF MEDULLARY-THYROID CARCINOMA USING AN IMMUNORADIOMETRIC ASSAY OF CALCITONIN - COMPARISON WITH GENETIC SCREENING IN HEREDITARY MEDULLARY-THYROID CARCINOMA [J].
BARBOT, N ;
CALMETTES, C ;
SCHUFFENECKER, I ;
SAINTANDRE, JP ;
FRANC, B ;
ROHMER, V ;
JALLET, P ;
BIGORGNE, JC .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (01) :114-120
[3]  
Bieglmayer C, 2002, WIEN KLIN WOCHENSCHR, V114, P267
[4]   Reduced parathyroid functional mass after successful kidney transplantation [J].
Bonarek, H ;
Merville, P ;
Bonarek, M ;
Moreau, K ;
Morel, D ;
Aparicio, M ;
Potaux, L .
KIDNEY INTERNATIONAL, 1999, 56 (02) :642-649
[5]  
CARNEY SL, 1995, MINER ELECTROL METAB, V21, P411
[6]   NORMAL CALCITONIN RESPONSE TO PENTAGASTRIN STIMULATION IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].
ESCALADA, J ;
TERUEL, JL ;
PAVON, I ;
VILA, T ;
NAVARRO, J ;
VARELA, C .
ACTA ENDOCRINOLOGICA, 1993, 129 (01) :39-41
[7]   Performance of different prediction equations for estimating renal function in kidney transplantation [J].
Gaspari, F ;
Ferrari, S ;
Stucchi, N ;
Centemeri, E ;
Carrara, F ;
Pellegrino, M ;
Gherardi, G ;
Gotti, E ;
Segoloni, G ;
Salvadori, M ;
Rigotti, P ;
Valente, U ;
Donati, D ;
Sandrini, S ;
Sparacino, V ;
Remuzzi, G ;
Perico, N .
AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (11) :1826-1835
[8]   Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin [J].
Grauer, A ;
Raue, F ;
Ziegler, R .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1998, 106 (04) :353-359
[9]   Sex-related C cell hyperplasia in the normal human thyroid: A quantitative autopsy study [J].
Guyetant, S ;
Rousselet, MC ;
Durigon, M ;
Chappard, D ;
Franc, B ;
Guerin, O ;
SaintAndre, JP .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (01) :42-47
[10]   Thyroid hormone metabolism and thyroid diseases in chronic renal failure [J].
Kaptein, EM .
ENDOCRINE REVIEWS, 1996, 17 (01) :45-63